CSL (CMXHF) Other Long-Term Liabilities : $982 Mil (As of Dec. 2023)

View and export this data going back to 2009. Start your Free Trial

What is CSL Other Long-Term Liabilities?

CSL's other long-term liabilities for the quarter that ended in Dec. 2023 was $982 Mil.

CSL's quarterly other long-term liabilities increased from Dec. 2022 ($867 Mil) to Jun. 2023 ($900 Mil) and increased from Jun. 2023 ($900 Mil) to Dec. 2023 ($982 Mil).

CSL's annual other long-term liabilities increased from Jun. 2021 ($545 Mil) to Jun. 2022 ($637 Mil) and increased from Jun. 2022 ($637 Mil) to Jun. 2023 ($900 Mil).

CSL Other Long-Term Liabilities Historical Data

The historical data trend for CSL's Other Long-Term Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CSL Other Long-Term Liabilities Chart

CSL Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Other Long-Term Liabilities

Get a 7-Day Free Trial

CSL Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Other Long-Term Liabilities	Get a 7-Day Free Trial															-	-	-	-	-

CSL Other Long-Term Liabilities Calculation

Other Long-Term Liabilities are the other liabilities on the balance sheet that do not need to be repaid within the next 12 months, but still need to be repaid over time. For instance, on Wal-Mart's balance sheet, there are items called Long Term obligations under capital leases, deferred income taxes, and redeemable non-controlling interest. These are all Other Long-Term Liabilities.

CSL Other Long-Term Liabilities Related Terms

Thank you for viewing the detailed overview of CSL's Other Long-Term Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

CSL (CMXHF) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CSL Ltd (OTCPK:CMXHF) » Definitions » Other Long-Term Liabilities

Comparable Companies

Traded in Other Exchanges

CSLLY:USA CSJ:Germany CSL:Australia

Address

655 Elizabeth Street, Melbourne, VIC, AUS, 3000

Website

https://www.csl.com

CSL is one of the largest global biotech companies and has two main segments. CSL Behring either uses plasma-derived proteins or recombinants to treat conditions including immunodeficiencies, bleeding disorders and neurological indications. Seqirus is now the world's second largest influenza vaccination business and was acquired in fiscal 2015. CSL has a strong R&D track record, and the product portfolio and pipeline include non-plasma products as the firm continues to broaden its scope. Originally formed in Australia as a government-owned entity, CSL now earns roughly half its revenue in North America and a quarter in Europe.